Sizzle,we have been here for a while and it looks the ship is getting ready to sail. I am in all three stocks too. New president, new well credentialed scientific advisors, FDA clinical approval at RGBP/BMSN this week, and now NIH funding for RGBP/BMSN announced this week too is awesome. As pointed out in my last post that Harry Lander has an incredible tech/science background as well as heavy duty business(Wallstreet) experience. This guy appears to be all about success. Harry Lander was absolutely needed to drive the businesses.
Keep in mind that the NR2F6 gene silencing work that was announced when Christine Ichim's initially joined Entest is now the process being studied preclinically for humans with Dr. Santosh Kesari, Professor of Neurosciences,at the John Wayne Cancer Institute. And now with the NCATS(National Center For Advancing Translational Sciences), funded by the National Institute of Health(NIH) If you recall that Christine Ichim's work with this was towards canine and feline leukemia. So one would think this would circle back to ENTB.
Company is now achieving a point of critical masss.
The base manipulation will come to an end some day soon for the bottom feeders. Btw enjoy your posts and optimistic view.
Best of luck.
JW12
